Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk

Published 29/04/2025, 13:22
© Reuters

Investing.com -- Shares in Hims Hers Health Inc (NYSE:HIMS) soared over 40% on Tuesday after the telehealth group announced a "long-term collaboration" with Novo Nordisk A/S (NYSE:NVO) to offer the Danish firm’s blockbuster Wegovy obesity drug on its platform.

In a statement, Hims & Hers said Americans will have access to a bundled offering that includes all dose strengths of Wegovy.

From this week, the treatment will be available at a "single, unified price" starting at $599 per month on the Hims & Hers platform.

Both companies said they are also developing a roadmap that combines Novo’s "innovative treatments" and Hims & Hers’ "ability to scale access to quality care."

Hims & Hers added that its platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.

Earlier this month, Hims & Hers said it was planning to sell Eli Lilly (NYSE:LLY)’s weight-loss drug, as part of a bid to widen its offerings to offset a possible impact from restrictions on selling copies of Wegovy.

Shares in Hims & Hers were hit in February after U.S. drug regulators removed Wegovy and the diabetes drug Ozempic, both of which are known chemically as semaglutide, from its shortage list.

Their presence on this list had allowed Hims & Hers to sell cheaper versions of Novo’s semaglutide.

 

(Reuters contributed reporting.)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.